The opioid drug that addicts don't like could be approved next spring
An experimental drug from Nektar Therapeutics Inc. is heading into regulatory review — and abusers of pain-killing opioid drugs may not like it.
The oral drug, called NKTR-181, would be the first full mu-opioid — "mu" marking one of three receptors of powerful, addictive opioids — to be developed in more than 50 years. But the San Francisco-based company (NASDAQ: NKTR) first may have to convince a Food and Drug Administration advisory panel that its rewards outweigh its risks for people with…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Ron Leuty Source Type: news
More News: Addiction | Food and Drug Administration (FDA) | Health Management | Pain | Pharmaceuticals